Presentation and outcomes of systemic non-Hodgkin's lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS

References

• Cote T R, Biggar R J, Rosenberg P S, Devesa S S, Percy C, Yellin F J, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. Int J Cancer 1997; 73: 645–650
   PubMed Web of Science ®Google Scholar
• Spina M, Carbone A, Vaccher E, Gloghini A, Talamini R, Cinelli R, et al. Outcome in patients with non-Hodgkin lymphoma and with or without human immunodeficiency virus infection. Clin Infect Dis 2004; 38: 142–144
   PubMed Web of Science ®Google Scholar
• Palella F J, Jr, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860
   PubMed Web of Science ®Google Scholar
• Tam H K, Zhang Z F, Jacobson L P, Margolick J B, Chmiel J S, Rinaldo C, et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002; 98: 916–922
   PubMed Web of Science ®Google Scholar
• Seiffert J E, Price W T, Gordon B. The California tumor registry: a state-of-the-art model for a regionalized, automated, population-based registry. Top Health Rec Manage 1990; 11: 59–73
   PubMedGoogle Scholar
• State of California Department of Health Standards, Cancer Surveillance Section. California Cancer Registry Data Standards and Assessment Unit. Cancer reporting in California: Abstracting and coding procedures for hospitals5th ed. 1998; 1
   Google Scholar
• International classification of diseases for oncology2nd ed., C Percy, V Van Holten, C Muir. World Health Organization, Geneva 1990
   Google Scholar
• American Hospital Association. AHA Guide to the Health Care Field2001–2002 ed. Health Forum LLC, Chicago 2001
   Google Scholar
• Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 06, 2005, Available at: http://aidsinfo.nih.gov. Accessed November 4, 2005
   Google Scholar
• Schag C C, Heinrich R L, Ganz P A. Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 1984; 2: 187–193
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al. AIDS Malignancy Consortium. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171–2178
   PubMed Web of Science ®Google Scholar
• Kaplan L D, Straus D J, Testa M A, Von Roenn J, Dezube B J, Cooley T P, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336: 1641–1648
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet F P, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98: 2339–2344
   PubMed Web of Science ®Google Scholar
• Navarro J T, Ribera J M, Oriol A, Romeu J, Sirera G, Mate J L, et al. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma. Leuk Lymphoma 2002; 43: 1837–1842
   PubMed Web of Science ®Google Scholar
• Robotin M C, Law M G, Milliken S, Goldstein D, Garsia R J, Dolan G M, et al. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med 2004; 5: 377–384
   PubMed Web of Science ®Google Scholar
• Lascaux A S, Hemery F, Goujard C, Lesprit P, Delfraissy J F, Sobel A, et al. Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas. AIDS Res Hum Retroviruses 2005; 21: 214–220
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Alba L, Ammassari A, Serraino D, Ciancio B C, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001; 15: 1483–1491
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003; 17: 1521–1529
   PubMed Web of Science ®Google Scholar
• Powles T, Imami N, Nelson M, Gazzard B G, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531–536
   PubMed Web of Science ®Google Scholar
• Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155–163
   PubMed Web of Science ®Google Scholar
• Little R F, Pittaluga S, Grant N, Steinberg S M, Kavlick M F, Mitsuya H, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101: 4653–4659
   PubMed Web of Science ®Google Scholar